Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Oric Pharmaceuticals Inc (ORIC)

179 + Investors. Track Smart Money conviction in ORIC. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +15
Streak
3Q ▲
Buyers last Q
52%

Smart Money Signals — ORIC

Based on 180 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added ORIC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
180 hedge funds hold ORIC right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +28% more funds vs a year ago

fund count last 6Q
+39 new funds entered over the past year (+28% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 52% buying

96 buying87 selling
Last quarter: 96 funds bought or added vs 87 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~38 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 33 → 30 → 36 → 38. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

42% of holders stayed for 2+ years

■ 42% conviction (2yr+) ■ 32% medium ■ 27% new
75 out of 180 hedge funds have held ORIC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Price up while funds trimmed (+50% value, -0% shares)

Value
+50%
Shares
0%
Last quarter: total value of institutional ORIC holdings rose +50% even though funds reduced share count by 0%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.
📈

Growing discovery — still being found

31 → 33 → 30 → 36 → 38 new funds/Q
New funds entering each quarter: 33 → 30 → 36 → 38. A growing number of institutions are discovering ORIC each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 52% veterans vs 31% newcomers

■ 52% veterans ■ 17% 1-2yr ■ 31% new
Entry-cohort mix of 183 holders: 96 (52%) are 2+ year veterans, 31 entered 1–2 years ago, and 56 (31%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 24% AUM from major funds

24% from top-100 AUM funds
41 of 180 holders rank in the top 100 by AUM, accounting for 24% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ORIC

In 2026 Q1, 96 hedge funds were net buyers of ORIC (38 opened a new position, 58 added to an existing one), while 87 reduced or exited (64 trimmed, 23 sold completely) — a 52% buyer ratio, indicating a slight buying edge. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 24% of total institutional value in ORIC is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +15 funds (more new holders than closures). Total institutional holders: 180.

Hedge Fund Ownership: ORIC

How many hedge funds hold ORIC — quarterly history vs. share price
Quarterly hedge fund ownership of ORIC vs. share price

Market Analysis: ORIC

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ORIC

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Oric Pharmaceuticals Inc (ORIC) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ORIC has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 47d ago
ORIC
+28.1%
XLV
+5.5%

ORIC outperformed XLV by +22.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 2d ago
ORIC
+0.0%
XLV
+0.0%

Since the filing became public, ORIC outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

19 top-rated funds 6 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
3.5
/ 10
conviction
Hedge Fund Positioning: ORIC
2026 Q2 Stats Unlock in 3 days 179 + Investors

Track Smart Money conviction in ORIC. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 179 165 8.48%
13F Shares 119M 120M -0.43%
Total Value $1.43B $953M 50.08%
New Positions 37 36 +1
Increased Positions 57 70 -13
Closed Positions 23 19 +4
Reduced Positions 63 34 +29
Total Calls 2 2 -
Total Puts 1 0 100%
PUT/CALL Ratio 0.5 0.0 Bullish

Statistics: ORIC

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

179 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ORIC. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 ORIC holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Column Group LLC 43.53% 3,540,777 $38.3M
2 AIHC Capital Management Ltd 39.77% 3,828,460 $41.5M
3 Sr One Capital Management, LP 4.81% 4,615,384 $50.0M
4 Nextech Invest Ltd. 3.68% 7,162,637 $77.6M
5 EcoR1 Capital, LLC 3.54% 6,728,116 $72.9M
6 NEXTBio Capital Management LP 3.52% 706,124 $7.6M
7 NEA Management Company, LLC 2.81% 4,118,621 $44.6M
8 Superstring Capital Management LP 2.78% 406,077 $4.4M
9 Euclidean Capital LLC 2.44% 989,410 $10.7M
10 First Turn Management, LLC 2.34% 2,017,284 $21.8M
11 Pfizer Inc 2.09% 372,904 $3.6M
12 Vivo Capital, LLC 1.83% 1,848,786 $20.0M
13 Jones Hill Capital LP 1.72% 747,313 $8.1M
14 Defilade Capital Management, L.P. 1.52% 1,047,690 $11.3M
15 Venrock Adviser, LLC 1.42% 4,319,765 $46.8M
16 MPM BioImpact LLC 1.24% 1,882,162 $20.4M
17 Sphera Funds Management LTD. 1.06% 752,983 $8.2M
18 Ishara Investments LP 0.98% 123,000 $1.3M
19 Silverarc Capital Management, LLC 0.83% 738,873 $8.0M
20 Integral Health Asset Management, LLC 0.81% 1,900,000 $20.6M
21 Siren, L.L.C. 0.66% 2,998,192 $32.5M
22 Blue Owl Capital Holdings LP 0.65% 400,000 $4.3M
23 Braidwell LP 0.49% 1,214,540 $13.2M
24 Orbimed Advisors LLC 0.40% 2,015,000 $21.8M
25 EntryPoint Capital, LLC 0.35% 72,712 $514K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Oric Pharmaceuticals Inc (ORIC)

What does the Smart Money Trend signal show for ORIC?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added ORIC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ORIC?

Slight buying edge — 52% buying: Last quarter: 96 funds bought or added vs 87 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ORIC holders?

Strong quality — 24% AUM from major funds: 41 of 180 holders rank in the top 100 by AUM, accounting for 24% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ORIC?

42% of holders stayed for 2+ years: 75 out of 180 hedge funds have held ORIC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Oric Pharmaceuticals Inc (ORIC) following the 2026 Q2 hedge fund 13F filings?

As of today, ORIC has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ORIC has gained +28.1% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →